If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
=== Myopathies with cores === 'Core myopathies' such as multicore myopathy and central core disease are characterized by sharply-demarcated areas devoid of oxidative enzymes NADH, SDH, and COX, in muscle fibres.
3) Regulations 1993 (S.I. 1993/1540) Firearms (Dangerous Air Weapons) (Scotland) Amendment Rules 1993 (S.I. 1993/1541) First Community National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1543) Mental Health Foundation of Mid Staffordshire National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1544) Special Trustees for the Royal London Hospital (Transfer of Trust Property) Order 1993 (S.I. 1993/1545) Child Resistant Packaging (Safety) (Amendment) Regulations 1993 (S.I. 1993/1546) Toys (Safety)(Amendment) Regulations 1993 (S.I. 1993/1547) Addenbrooke's National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1564) Foreign Fields (Specification) (Amendment) Order 1993 (S.I. 1993/1565) Foreign Fields (Specification) (No. 2) Order 1993 (S.I. 1993/1566) Reconstitution of the Dearne and Dove Internal Drainage Board Order 1993 (S.I. 1993/1570) European Communities (Designation)(No. 2) Order 1993 (S.I. 1993/1571) House of Commons Disqualification Order 1993 (S.I. 1993/1572) Child Abduction and Custody (Parties to Conventions) (Amendment) (No. 2) Order 1993 (S.I. 1993/1573) Extradition (Hijacking) (Amendment) Order 1993 (S.I. 1993/1574) Iraq (United Nations) (Sequestration of Assets) (Isle of Man) Order 1993 (S.I. 1993/1575) Family Law (Northern Ireland) Order 1993 (S.I. 1993/1576) Family Law (Northern Ireland Consequential Amendments) Order 1993 (S.I. 1993/1577) Fire Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/1578) Social Security (Amendment) (Northern Ireland) Order 1993 (S.I.
=== Dissolving iron and steel === Alum solution has the property of dissolving steels while not affecting aluminium or base metals. Alum solution can be used to dissolve steel tool bits that have become lodged in machined castings.
== Medical applications == RNA, initially deemed unsuitable for therapeutics due to its short half-life, has been made useful through advances in stabilization. Therapeutic applications arise as RNA folds into complex conformations and binds proteins, nucleic acids, and small molecules to form catalytic centers. RNA-based vaccines are thought to be easier to produce than traditional vaccines derived from killed or altered pathogens, because it can take months or years to grow and study a pathogen and determine which molecular parts to extract, inactivate, and use in a vaccine. Small molecules with conventional therapeutic properties can target RNA and DNA structures, thereby treating novel diseases. However, research is scarce on small molecules targeting RNA and approved drugs for human illness. Ribavirin, branaplam, and ataluren are currently available medications that stabilize double-stranded RNA structures and control splicing in a variety of disorders. Protein-coding mRNAs have emerged as new therapeutic candidates, with RNA replacement being particularly beneficial for brief but torrential protein expression. In vitro transcribed mRNAs (IVT-mRNA) have been used to deliver proteins for bone regeneration, pluripotency, and heart function in animal models. SiRNAs, short RNA molecules, play a crucial role in innate defense against viruses and chromatin structure. They can be artificially introduced to silence specific genes, making them valuable for gene function studies, therapeutic target validation, and drug development.
Sources: en.wikipedia.org
"Any individual who is not a member of a federally recognized Cherokee tribe, in academia or otherwise, is hereby discouraged from claiming to speak as a Cherokee, or on behalf of Cherokee citizens, or using claims of Cherokee heritage to advance his or her career or credentials." – Joint Council of the Cherokee Nation and the Eastern Band of the Cherokee Indians The United Keetoowah Band did not sign or approve the resolution. The Cherokee Nation acknowledges the existence of people of Cherokee descent "... in states such as Arkansas, Kansas, Missouri, and Texas," who are Cherokee by ancestry but who are not considered citizens of the Cherokee Nation.
In 2010, Arby's opened a restaurant at Ft. Bliss, their first location at an American military base under a deal that the Wendy's/Arby's Group had signed with the Army and Air Force Exchange Service to open restaurants at bases both in the United States and overseas. Only American military personnel and some of their guests can patronize the Arby's locations situated on the military bases and operated by the Post Exchange. There were two different attempts to operate franchises in the United Kingdom. GSR Restaurant Group opened their first Arby's franchise location in London in 1992 followed by a second location the following year in Glasgow. These were also the first locations to open in Europe, but both were forced to close by 1994. In 2001, Barown Restaurants opened two Arby's franchise locations in Southampton, Hampshire, and Sutton, London, but both were forced to close after operating for a few months. On June 13, 2011, Wendy's/Arby's Group Inc. announced that it would sell the majority of its Arby's chain to Roark Capital Group while maintaining an 18.5% stake in the company. At the time of the sale, Arby's was experiencing an operating loss for the year of $35 million with 350 Arby's franchisees more than 60 days late in royalty payments and 74 low performing franchised units and 96 company-owned units forced to close. Despite its cash flow problem, Arby's also reported that it had six months of sales growth at established stores in the United States which it had attributed to its new turnaround plan that it had recently launched.
== Therapeutics == Several mimetics of ELA have been developed for therapeutic purposes. Amgen has created a camel antibody and a small molecule agonist capable of mimicking the function of ELA towards it cognate receptor APLNR. The latter has entered phase 1 clinical trials for heart failure and acute kidney disease. Bristol Myers Squibb has also created its own small molecule agonist of APLNR. An opinion published in the Lancet in 2019 suggested that ELABELA could be used to treat intrauterine growth restriction and maternal morbidity linked to eclampsia.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.